Unicycive Therapeutics, Inc. (UNCY)
NASDAQ: UNCY · Real-Time Price · USD
6.54
-0.11 (-1.65%)
Apr 10, 2026, 1:27 PM EDT - Market open
Unicycive Therapeutics Employees
As of December 31, 2025, Unicycive Therapeutics had 22 total employees, including 21 full-time and 1 part-time employees. The number of employees decreased by 1 or -4.35% compared to the previous year.
Employees
22
Change (1Y)
-1
Growth (1Y)
-4.35%
Revenue / Employee
n/a
Profits / Employee
-$1,207,045
Market Cap
165.06M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 22 | -1 | -4.35% | 21 | 1 |
| Dec 31, 2024 | 23 | 9 | 64.29% | 22 | 1 |
| Dec 31, 2023 | 14 | 2 | 16.67% | 14 | 0 |
| Dec 31, 2022 | 12 | 3 | 33.33% | 12 | 0 |
| Dec 31, 2021 | 9 | 8 | 800.00% | 9 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
Employee RankingsUNCY News
- 1 day ago - Unicycive Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference - GlobeNewsWire
- 11 days ago - Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 7 weeks ago - Important Notice to Long-Term Shareholders of Unicycive Therapeutics, Inc. (UNCY): Grabar Law Office Is Investigating Claims on Your Behalf - Newsfile Corp
- 2 months ago - Unicycive Therapeutics to Participate in a Fireside Chat at Guggenheim's Emerging Outlook: Biotech Summit - GlobeNewsWire
- 2 months ago - UPDATE - Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission - GlobeNewsWire
- 2 months ago - Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission - GlobeNewsWire
- 3 months ago - Unicycive Therapeutics Announces Resubmission of New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) - GlobeNewsWire
- 4 months ago - Important Notice to Long-term Shareholders of Unicycive Therapeutics, Inc. (UNCY): Grabar Law Office Is Investigating Claims on Your Behalf - Newsfile Corp